MPNST — Malignant Peripheral Nerve Sheath Tumour

What Is an MPNST (Nerve Sheath Tumour Cancer)?

A malignant peripheral nerve sheath tumour — MPNST for short — is a cancer that develops from the supporting cells that form the insulating sheath around a peripheral nerve, most often the Schwann cells. Peripheral nerves are the electrical "cables" that run from the spinal cord out to the limbs and trunk; each is wrapped in a protective layer, and it is this layer, not the nerve signal itself, that the tumour grows from. Because of this origin, MPNST was historically also called a malignant schwannoma or neurofibrosarcoma, but MPNST is now the accepted name.

MPNST belongs to the family of soft tissue sarcomas — rare cancers that arise from connective tissues rather than from organs. You can read about the whole group on our sarcoma — overview hub. Within that family, MPNST is uncommon (roughly 5–10% of soft tissue sarcomas) but important, because it behaves more aggressively than many other subtypes and is closely tied to a genetic condition. It usually appears in adults between 20 and 50, can occur anywhere a nerve runs, and most often arises deep in the thigh, buttock, upper arm, or alongside the spine.

What makes MPNST distinct from a common lipoma or a benign nerve tumour is its behaviour: it grows quickly, can invade nearby structures, and has a meaningful tendency to spread to the lungs. That is why a deep lump that is enlarging — especially one accompanied by nerve symptoms — should never be assumed harmless and should be assessed by a sarcoma specialist before anyone operates on it.

MPNST and Neurofibromatosis (NF1): Why the Link Matters

The connection between MPNST and neurofibromatosis type 1 is one of the most important things to understand about this cancer. NF1 is an inherited condition caused by a fault in the NF1 gene, which normally acts as a brake on cell growth. People with NF1 develop multiple benign nerve tumours called neurofibromas, along with café-au-lait skin patches and other features. In about half of all MPNST cases, the cancer arises in someone with NF1 — usually when a deep, branching plexiform neurofibroma undergoes malignant transformation.

The practical message for anyone living with NF1 is straightforward: a lifetime risk of MPNST of roughly 8–13% means warning signs deserve immediate attention rather than reassurance. Our dedicated guide to neurofibromatosis (NF1) and MPNST risk explains who should be monitored, how often, and which symptoms call for an urgent MRI. The two changes that matter most are a neurofibroma that suddenly grows and one that becomes persistently painful — particularly pain that disturbs sleep.

The other recognised risk factor is previous radiation therapy: a small number of MPNSTs arise years after radiation given for an unrelated cancer, within the irradiated field. Most MPNSTs in people without NF1, however, are sporadic — they appear with no family history and no prior radiation. A new nerve-region lump with numbness or tingling suggesting nerve involvement warrants evaluation regardless of whether NF1 is present.

Symptoms: How an MPNST Announces Itself

Because an MPNST begins inside a nerve, its symptoms are often a mix of a mass and nerve dysfunction — a combination that should always prompt specialist assessment. The classic picture is a deep, firm lump that is getting bigger, accompanied by one or more of the following:

• Numbness or tingling (pins and needles) in the skin supplied by the affected nerve
• Pain along the nerve — often new, persistent, and sometimes worse at night
• Weakness in a muscle group, or difficulty with a specific movement of the limb
• An electric-shock sensation when the lump is tapped (a positive Tinel's sign over a nerve mass)

A benign neurofibroma can also cause mild versions of these, so it is the tempo of change that distinguishes worry from reassurance: rapid growth over weeks to a few months, new or worsening pain, and a lump that has grown beyond about 5 cm are the features that move a nerve mass into the "needs urgent imaging" category. In Hyderabad, far too many of these lumps are first removed at a general surgery clinic without imaging or biopsy — a costly mistake when the lesion turns out to be a sarcoma, because it compromises the one operation that matters most.

How an MPNST Is Diagnosed and Graded

Diagnosing an MPNST accurately — and distinguishing it from a benign neurofibroma — requires a careful, ordered work-up. Removing a deep nerve lump "to see what it is" without this sequence is one of the most damaging errors in sarcoma care, because an unplanned operation can scatter cancer cells and force a far bigger second surgery. At CION, the pathway is staged deliberately:

Step 1 — MRI of the Lump

MRI is the imaging investigation of choice. It shows the tumour's size, depth, and its relationship to the parent nerve, muscle, and major vessels. Certain features — a large size, irregular margins, internal necrosis, and a "target" pattern breaking down — raise suspicion that a neurofibroma has turned malignant. MRI also maps the surgical margin in advance.

Step 2 — Core Needle Biopsy

A core needle biopsy takes a small tissue sample to confirm the diagnosis and grade under the microscope, ideally planned so the needle track can later be removed with the tumour. The pathologist looks at how abnormal the cells are and how fast they are dividing, supported by immunohistochemistry (markers such as S100 and SOX10, and loss of H3K27me3, help confirm nerve-sheath origin).

Step 3 — Grading: Low vs High

MPNSTs are graded by how aggressive the cells look. The majority are high-grade, which signals faster growth and a higher chance of spread — and usually means radiation and chemotherapy are considered alongside surgery. A minority are low-grade. The grade, together with the tumour's size and depth, drives the entire treatment plan.

Step 4 — Staging Scans

Because MPNST can spread to the lungs, a CT scan of the chest is performed to check for metastases. A PET-CT may be used in NF1 patients to identify which of several neurofibromas is the malignant one — the "hottest" lesion on PET is the one to biopsy.

How MPNST Is Treated

MPNST treatment is multidisciplinary — decided together by surgery, radiation, and medical oncology at the tumour board. The backbone is surgery, with radiation and chemotherapy added according to grade, size, and location.

Treatment intensity is tailored to the individual: a small, low-grade, completely removable MPNST may need surgery alone, while a large high-grade tumour deep in the thigh will usually have radiation and a chemotherapy discussion built into the plan. For the full surgical pathway and what to expect, see our guide to sarcoma treatment in Hyderabad.

Prognosis: What Outcomes Depend On

MPNST is one of the more challenging soft tissue sarcomas, but outcomes vary widely from patient to patient, and a frank discussion is better than a single statistic. The factors that most strongly influence the outlook are the completeness of surgical removal (a clear R0 margin is the single biggest favourable factor), the tumour's grade and size, its location (limb tumours are generally more removable than those deep alongside the spine or pelvis), and whether it has already spread to the lungs at diagnosis.

Historically, MPNSTs arising in NF1 were reported to do somewhat worse than sporadic ones, partly because they are often found later and at a larger size — which is exactly why early imaging of a changing neurofibroma matters so much. With modern multidisciplinary care, a completely resected, localised MPNST has a meaningfully better outlook than these older figures suggest. Long-term surveillance — periodic MRI of the surgical site and CT of the chest — is part of the plan, because the time to act on a recurrence or a lung metastasis is when it is small.

Indicative Cost in Hyderabad

Costs are indicative. A personalised estimate is provided after your CION consultation. EMI options and cashless support through major TPAs, Aarogyasri, CGHS, ECHS & ESI are available for eligible patients.

Why Patients Choose CION for MPNST Care

MPNST is rare and aggressive — it needs a team that treats sarcoma regularly, not occasionally. Here is why patients across Telangana trust CION.

Don't Wait With a Changing Nerve Lump

With MPNST, early specialist care and a planned first operation give the best chance of cure. Whether you have a suspicious lump, an NF1 history, or a biopsy that says MPNST, talk to our sarcoma team first.